Hilary Calvert, Director of the Cancer Research Unit, University of Newcastle Upon Tyne. : 00 32 27741619 or Fax: 00 32 2273545). Professor Horwich was elected as a Fellow of the Academy of Medical Sciences in 2003. Recent advances in the treatment of prostate cancer. 6]. Patients would then be monitored each month while off therapy; any rise in PSA level was taken to indicate progression. Professor Horwich was elected as a Fellow of the Academy of Medical Sciences in 2003. Locally Advanced Prostate Cancer Biochemical Recurrence after Radiotherapy: Use of Cyclic Androgen Withdrawal Therapy. Disclosure: Shareholder of Genesis Health Care (P/L). Dr Mark Stevens is a Senior Staff Specialist Radiation Oncologist to the Northern Sydney Cancer Centre and Visiting Medical Officer to Gosford Hospital's Central Coast Cancer Centre and Genesis Cancer Care (Mater-St Vincent's and Macquarie Hospitals, Sydney). If you do not receive an email within 10 minutes, your email address may not be registered, Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, U.K. Department of Radiotherapy and Oncology, Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, U.K. Sir Murray Brennan, Vice President of International Programs and Director of the Bobst International Center, Memorial Sloan Kettering Cancer Center, New York. All funding for this site is provided directly by ESMO. Bridget Robinson, Professor and Clinical Director of Mackenzie Cancer Research Group, University of Otago, Christchurch; Medical Oncologist, Christchurch Hospital. Before registration in the study patients gave signed informed consent after discussion and review of the patient‐information sheet approved by the Royal Marsden Hospital Research Ethics Committee. The South‐Western Oncology Group Trial 9346 is for patients with clinical Stage D2 carcinoma of the prostate who have six or fewer bone metastases and no visceral organ metastases. Prevalence of Bilateral Testicular Germ Cell Tumours and Early Detection Based on Contralateral Testicular Intra‐epithelial Neoplasia. Lecture Title: 'Partnerships for Progress'. Eleven of the 16 patients had a stable hormone response and stopped therapy 3–9 months (mean 5.5) from the start of treatment. Prolonged response to a single androgen suppression phase in a subpopulation of prostate cancer patients. The Cochrane Database of Systematic Reviews, https://doi.org/10.1046/j.1464-410x.1998.00521.x. Use the link below to share a full-text version of this article with your friends and colleagues. Lecture Title: 'Design, Evaluation, and Development of Novel Anticancer Drugs'. Synchronous presentation of different testicular tumours. INTRATUBULAR GERM CELL NEOPLASIA OF THE CONTRALATERAL TESTIS IN TESTICULAR CANCER. Bilateral testicular cancer: a preventable problem? Lecture Title: 'High Dose Chemotherapy in Cancer Management'. He subsequently became Reader in Prostate Cancer Studies in 1999 and Professor of Uro-Oncology in 2003. These experiments were based on mice bearing LNCaP tumours that were treated with testosterone implants beginning 2 weeks after castration, using cycles of testosterone replacement for 1 week and withdrawal for 2 weeks, repeated until PSA levels no longer returned to baseline on androgen withdrawal. Selecting and Counseling Patients on Appropriate Treatment of Prostate Cancer. Registered address: The Royal Marsden Cancer Charity, Fulham Road, London, SW3 6JJ. Mark Dewhirst, Gustavo S. Montana Professor of Radiation Oncology, Duke University School of Medicine. His research focuses on how we might use new targeted treatments that boost the immune system’s ability to fight cancer, known as immunotherapies. Cycles of treatment and treatment withdrawal were repeated until the regulation of serum PSA level became androgen‐independent. Please check your email for instructions on resetting your password. The mean (range) period off therapy in patients with bone metastases was 8 (3–13) months. Working off-campus? Patients who had undergone previous hormonal therapy were excluded. Ted Lawrence, Professor of Radiation Oncology, Michigan University. Lecture Title: 'From Cancer Genomics to New Molecular Therapeutics'. Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username, I have read and accept the Wiley Online Library Terms and Conditions of Use. M. D. Mason, MRCP, FRCR, Senior Registrar in Radiotherapy. Intermittent endocrine therapy for advanced prostate cancer. Semen quality in testicular tumour and CIS in the contralateral testis.